新闻 > 国内
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China

复星医药上半年营收增两成 研发费用和海外营收增长逾50%

2017-08-30 10:36:39   央广网

央广网上海8月30日消息(记者吴善阳 通讯员易锦媛)复星医药(股票代码:600196.SH,02196.HK)今天公布2017年中期业绩。报告期内,复星医药集团实现营业收入人民币835,302.26万元,较2016年同期增长20.41%。其中药品制造与研发业务实现营业收入人民币577,577.88万元,较2016年同期增长19.12%;医疗服务业务实现营业收入人民币101,214.96万元,较2016年同期增长34.39%。复星医药集团在中国大陆实现营业收入人民币688,415.85万元,较2016年同期增长14.52%;在海外国家或地区实现营业收入人民币146,886.41万元,较2016年同期增长58.63%。

复星医药董事长陈启宇表示,2017年上半年,在全球及中国经济仍充满挑战和不确定性的严峻形势下,国家医疗体制改革持续深化,制药工业增速有所恢复但仍维持低位运行,而医疗技术及医疗服务仍然受益于政策,面临快速发展机遇。复星医药秉持“持续创新、乐享健康”的经营理念,围绕医药健康核心业务,坚持产品创新和管理提升,积极推进内生式增长、外延式扩张、整合式发展,主营业务继续保持均衡增长。

  研发投入持续加强

复星医药集团注重创新研发,拥有国家级企业技术中心,已形成国际化的研发布局和较强的研发能力,通过在中国(上海、重庆、台北)、美国(旧金山、波士顿)、以色列、瑞典的布局建立互动一体化的研发体系。目前,复星医药集团研发人员已逾千人。

复星医药集团以创新研发为最核心的发展驱动因素,持续加强研发投入。报告期内,复星医药集团研发投入共计人民币62,603.55万元,较2016年同期增长28.12 %,其中,研发费用人民币46,132.01万元,较2016年同期增长50.15%。药品制造与研发板块的研发投入为人民币52,963.79万元,较2016年同期增长24.93%,其中,研发费用为人民币36,492.25万元,较2016年同期增长50.46%,占药品制造与研发板块业务收入的6.3%。

截至报告期末,复星医药集团有6个单抗品种(11个适应症)已获批中国临床,其中2个产品已经进入临床三期;4个1.1类小分子创新药已获得临床批文;在研新药、仿制药、生物类似药及疫苗等项目173项(其中:小分子创新药11项、生物创新药9项、生物类似药12项、改良型创新药2项、国际标准的仿制药133项、预防用生物制品4项、中药2项),8个项目正在申报进入临床试验、25个项目正在进行临床试验、33个项目等待审批上市,预计这些在研产品将为集团后续经营业绩的持续发展奠定良好基础。

同时,复星医药集团通过组建合营公司、成立科技创新孵化平台等多元化合作方式,采用技术引进和“深度孵化”的模式衔接全球前沿创新技术,实现全球创新前沿技术的转化落地,促进对接国际领先的科技创新技术和项目,进一步提升创新能力、推进国际化进程。

上一页1/2下一页
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China

相关阅读

404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
分享到:
0 0
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China

美图推荐

404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China

为您推荐

加载更多>>
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/10000159/20170830/31230130.html
Server: cms-8-252
Date: 2024/11/25 14:48:00

Powered by China
China